News and Trends 25 Oct 2016 The First Peanut Allergy Therapy might soon hit the Shelves …first French Biotech to enter the NASDAQ, aims to be the first to attain approval for a food allergy therapy. The company’s lead pipeline candidate is Viaskin Peanut, a treatment… October 25, 2016 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Best in Biotech 18 Mar 2025 Cancer vaccines: 11 biotechs to keep an eye out for …some challenges with regard to immunogenicity – the ability of an antigen to provoke an immune response. As various biotechs across the world specialize in the production of cancer vaccines… March 18, 2025 - 14 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
More News! 16 Nov 2022 Mineralys has positive topline results from trial evaluating treatment of hypertension …a safe and well-tolerated profile. The data from the Target-HTN trial demonstrated no notable effects on serum cortisol, supporting the selectivity of MLS-101 for aldosterone synthesis. Treatment-emergent, serious adverse events… November 16, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 13 Jul 2022 Development of cancer therapeutics accelerated by end-to-end single-cell multi-omics services …for a rich characterization of tumor evolution and heterogeneity. This must be done at a much higher resolution compared to bulk next-generation sequencing. This enables detection of rare events, at… July 13, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
Interview 14 Nov 2022 In depth interview: AstraZeneca/Sanofi RSV drug Beyfortus …Sanofi answered some questions from Labiotech.eu about the news for our in-depth newsletter on children’s diseases. When it came to finding a solution, what were the steps involved, and how… November 14, 2022 - 9 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 17 Jan 2017 This Herpes Cure is Proving to Work Better than its Predecessors …of new viral DNA copies, pritelivir prevents the whole process by inhibiting the helicase-primase complex that ‘opens’ the original DNA chain in order to be copied. In addition, it does… January 17, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 22 Feb 2018 GW Pharma’s Latest Cannabinoid Drug Pegged Back by a Placebo in Phase II …while the drug caused adverse events in an extra 25% of patients in comparison with the placebo arm. However, GW will not give up on the candidate just yet as… February 22, 2018 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
In Depth 27 Apr 2017 Spain: An Emerging Star in the European Biotech Community …boasts more than 15 years’ tradition in drug discovery and preclinical research. For more than 10 years, BioCat, the biotech catalyst for Catalonia, organizes events at all levels connecting the… April 27, 2017 - 6 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 21 Nov 2016 “We are Pioneering Cell Therapy to Cure NASH and Fibrotic Disease” …diverse interests and future direction. Promethera is the new kid on Belgium’s biotech block in Louvain-la-Neuve, and it’s hatching plans to make a splash with an IPO next spring. The… November 21, 2016 - 7 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
In Depth 29 Aug 2025 Can genetically modified crops help us adapt to climate change? …increasing likelihood of extreme weather events. This includes the biotech sector, which, among other solutions, has long been working on the development of genetically modified crops. The question is, can… August 29, 2025 - 14 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 12 Sep 2022 Cuffless device worn 24/7 can lower blood pressure, says Aktiia …BP reduction and reduction of cardiovascular events is undisputed, irrespective of the mechanism for the reduction. Aktiia’s cuffless device empower people Josep Sola, Founder and chief technology officer at Aktiia,… September 12, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
More News! 8 Nov 2022 ISA Pharmaceuticals’ Amplivant adjuvant boosts immune response in SLP immunotherapy ISA Pharmaceuticals B.V, a Netherlands-based clinical stage biotech developing immunotherapies to treat cancers and infectious diseases has had a phase 1 clinical study published. The study, using ISA Pharmaceuticals’ Amplivant… November 8, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email